IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX: COR) Chairman, President and CEO, Roger G. Stoll, Ph.D., announced at the Bear Stearns 20th Annual Healthcare Conference held in New York City that the Company has submitted the AMPAKINE® CX717 Investigational New Drug (“IND”) Application for the treatment of Attention Deficit Hyperactivity Disorder (“ADHD”) with the Division of Psychiatry Products of the Food and Drug Administration (“FDA”). Dr. Stoll mentioned that filing the IND was a high priority for both the Company and for patients with this affliction given the promising data generated last year in a small Phase IIa pilot study in this population. That study showed statistical significance for changes in the ADHD rating scale for CX717 without the cardiovascular and other side effects seen with the current stimulant-based treatments.
